Not actual patients.
Designed to fit
your lifestyle
Why HYMPAVZI?
Learn what sets HYMPAVZI apart.
Prefilled, fixed-dose† pen
A set dose comes in each pen, so you don't need to mix or measure.
Innovative
HYMPAVZI works to help achieve hemostasis (how your body stops or prevents bleeding) through rebalancing the clotting process.
Subcutaneous delivery
HYMPAVZI is injected under the skin, not into a vein.
No mandatory treatment-related lab monitoring
Talk to your doctor about lab monitoring that may be necessary for your condition.
- In the phase 3 BASIS study, the primary objective was to measure the annualized bleed rate (ABR) of treated bleeds with HYMPAVZI prophylaxis vs on-demand factor-based treatment and factor-based prophylaxis treatment after 12 months. 92% reduction in treated bleed on HYMPAVZI compared with on-demand factor based treatment (3.2 ABR vs 39.9 ABR). 35% reduction in treated bleeds on HYMPAVZI compared with routine prophylaxis treatment (5.1 ABR vs 7.9). Individual results may vary.
- For children ages 6 to less than 12, the first dose (loading dose) is 150 mg on day 1. Then a weekly (maintenance) dose of 75 mg as prescribed by your healthcare provider. For adults and adolescents 12+, the first dose (loading dose) is 300 mg on day 1. Then a weekly (maintenance) dose of 150 mg as prescribed by your healthcare provider. If more than 1 injection is required to deliver a complete dose, administer each injection at a different site.
Download the patient brochure to find out how HYMPAVZI fits your lifestyle.
Learn how HYMPAVZI works